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1  | BACKGROUND
Epinephrine HFA is a proposed replacement for Epinephrine chlo‐
rofluorocarbon (CFC) (Primatene® Mist CFC), an OTC asthma me‐
tered dose inhaler (MDI) that was removed from the market due to 
the environmental effects of its CFC propellant.1 Compared to the 
previous Epinephrine CFC, the newly formulated Epinephrine MDI 
contains hydrofluoroalkane (HFA) propellant along with other ingre‐
dients such as polysorbate 80, ethanol, and very low amount of thy‐
mol (2‐isopropyl‐5‐methylphenol), which is used as an antioxidant.
Previous findings demonstrated the safety of orally administered 
thymol through acute and subacute toxicity tests.2,3 Furthermore, 
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Abstract
Epinephrine HFA (Primatene® Mist) is a newly formulated asthma metered dose in‐
haler developed to replace the previous Primatene® Mist CFC. The formulation of 
Epinephrine HFA contains thymol, a substance recognized to be safe by the FDA. 
Although the content of thymol contained in Epinephrine HFA is much lower com‐
pared to many common foods and medications available, there are no known non‐
clinical data about the chronic toxicity of thymol through inhalation. Two sequential 
6‐month studies of identical design were conducted to assess the chronic toxic‐
ity of inhaled thymol in mice. Four treatment groups, (a) Air; (b) vehicle control; (c) 
Article‐1 (thymol 0.1%); and (d) Article‐2 (thymol 0.5%) were assessed in 128 mice for 
26 weeks. The mice were sacrificed at the end of the treatment period and a histo‐
pathologic evaluation was performed with respect to lungs, bronchial lymph nodes, 
nasal passages/nasopharynx, and trachea. Forty‐five pathologic assessment param‐
eters	(PAPs)	were	evaluated.	In	total,	5591	data	points	from	487	mouse	organs	were	
assessed. Chronic toxicity index was calculated for 16 PAPs that had multiple histo‐
pathologic abnormal observations. The t tests were conducted for these 16 PAPs 
(Articles‐1 and 2 versus Air and vehicle control, respectively), and all P‐values were 
greater than .05 indicating no significant differences between all treatment groups. 
An evaluation was also conducted for 25 PAPs that had only a very small number of 
pathologic abnormalities. No significant differences for chronic toxicity were found 
when comparing mice under long‐term repeated exposure of high doses of inhaled 
thymol and mice that inhaled no thymol.
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according to the Code of Federal Regulations: “Thymol is an essen‐
tial oil that is extracted from thyme, mandarin and tangerine oils 
and is FDA approved when used as a synthetic flavoring (21 CFR 
172.515), a preservative and indirect food additive of adhesives (21 
CFR 175.105). The source plant (thyme), from which thymol is ex‐
tracted, is generally recognized as a safe substance (GRASS) by FDA 
(21 CFR 182.10, 21 CFR 182.2)”.4
Historic	 findings	 from	 as	 early	 as	 1964	 have	 demonstrated	
the safety of thymol.2,3 In an acute toxicity study, the oral LD50 
of thymol in rats was found to be 980 mg/kg.2 By comparison, 
common products such as vitamin D and caffeine have an LD50 of 
10 mg/kg and 200 mg/kg respectively in rats.5 In another study, 
no adverse effects were observed on gross pathology, hematol‐
ogy, body weight, food intake, and organ weight from a thymol 
amount of 10 000 ppm (300 mg kg−1 d−1) given to rats in their 
diet for 19 weeks.3 As an inter‐model comparison, the sub‐chronic 
relative thymol exposure of 300 mg kg−1 d−13 corresponds to a 
thymol exposure of 300 000 times greater than that contained in 
Epinephrine HFA (<0.001 mg kg−1 d−1). These studies also suggest 
that thymol, even at relatively high amounts, is considered a safe 
substance.
In addition, thymol is a common ingredient in many products 
such as perfumes, food flavorings, mouthwashes, pharmaceutical 
preparations, and cosmetics.6 As set forth in Appendix‐1 of the 
Federal Register dated 18 January 2006, “Inhalation exposure to 
thymol already occurs from contact with foodstuffs and seasonings 
containing thymol as it is FDA approved when used as a direct food 
additive and is generally recognized as safe by FDA as a spice, natural 
oil, oleoresin, or natural extract…” 4
Compared to various food and medication products including 
Halothane, a thymol containing inhalation medication that was avail‐
able	for	over	40	years,	the	thymol	content	contained	in	Epinephrine	
HFA is substantially less than in many food products7 and medica‐
tions that have been proven to be safe (Table S1). Therefore, the low 
exposure to thymol in the Epinephrine HFA formulation is expected 
to be minimal and is not expected to add any significant safety risk.
Although thymol is used in consumer food and hygienic prod‐
ucts, and there have been significant preclinical and human studies 
on the effects of thymol in a broad range of applications, there are no 
known nonclinical data about the chronic toxicity of thymol through 
inhalation. Therefore, this paper assesses the chronic effects of in‐
haled thymol in lungs and respiratory tracts using a mouse model.
2  | MATERIAL S AND METHODS
Two sequential 6‐month studies of identical design were conducted 
to assess the chronic toxicity of thymol through inhalation in mice. 
Both chronic toxicity studies were conducted in accordance with 21 
CFR §58, Good Laboratory Practice for Nonclinical Laboratory Studies. 
The study was conducted in accordance with the Basic & Clinical 
Pharmacology & Toxicology policy for experimental and clinical 
studies.8
2.1 | Test articles
There are four treatment groups in each study: (a) Group‐1 is nega‐
tive control containing only ambient air; (b) Group‐2 is Vehicle 
Control that also served as negative control. This control article 
contained the same ingredient as Epinephrine HFA, but without the 
active ingredient (epinephrine) and the study substance thymol; (c) 
Group‐3	is	test	Article‐1	containing	0.1%	of	thymol;	and	(d)	Group‐4	
is test Article‐2 containing 0.5% of thymol. The two test articles were 
prepared using the same materials and ingredients as currently used 
to produce Epinephrine HFA, but without the active ingredient of 
epinephrine. The amount of thymol in the two test articles is 10 and 
50 times the amount of thymol in the Epinephrine HFA formulation.
All three articles (Vehicle, Article‐1, and Article‐2) were pre‐
pared by Armstrong Pharmaceuticals, Inc under cGMP. The thymol 
amounts were tested and met the specification before they were 
released by Armstrong. At the end of the 6‐month studies, these ar‐
ticles were retested and confirmed to have good stability of thymol 
with all specifications met.
2.2 | Test animals
Male and female CD‐1 mice with weights of approximately 30 g and 
age of 7 weeks were purchased from Harlan, Indianapolis, IN. All 
animals were free of pathogens and housed in a clean environment 
with ad libitum access to water and food, and kept in a temperature 
(64‐79°F)	 controlled	 environment	 maintained	 on	 a	 12‐hour	 light/
dark cycle. The routine diet for mice was 2016 Teklad Global 16% 
Protein Rodent Diet, purchased from Harlan Laboratories. No di‐
etary contaminants were expected to interfere with the outcome 
of this study. All standard animal housing and handling procedures 
including sacrifice of the animals conformed to the lab facility stand‐
ard operating procedures (SOPs), NIH Guide for the Care and Use 
of Laboratory Animals, and GLP guidelines. All procedures were ap‐
proved by the Institutional Animal Care and Use Committee (IACUC).
2.3 | Chronic toxicity study design
All treatment procedures were identical in the two sequential 6‐
month studies. Within each study, animals were randomly assigned 
to one of the four treatment groups, with each group consisting of 
eight male and eight female CD‐1 mice. Unique IDs were given to the 
animals. Each treatment group was subject to only one article. When 
combined, the total number of animals in each treatment group was 
32,	with	a	1:1	ratio	of	male	to	female	mice.	In	total,	128	(=2	×	4	×	16,	
two sets of study, four treatment groups and 16 animals per group) 
mice were studied as summarized in Table 1.
In the studies, the test article was sprayed into a specially de‐
signed stainless steel 21.5‐L breathing tank as shown in Figure 1. 
The tank size is designed such that the total breath volume of all 
eight mice in the 10‐minute study time (1.8 L) is less than 10% of the 
tank size (21.5 L). The internal wall of the tank is electrically polished 
so that the thymol adsorption will be reduced to minimal. Eight mice 
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were mounted to the tank with four mice on each side using small 
animal restraints. At the start of each treatment session, 15 sprays 
of test article were sprayed into the precleaned tank following the 
same spray procedures described in the Epinephrine HFA insert. In 
order to ensure consistent concentration of test article, a stirring fan 
installed	inside	the	tank	was	set	at	400	RPM	and	was	started	before	
the first spray of the test articles. Thirty seconds after the last spray 
(t = 0 minute), eight mice were mounted to the inhalation chamber 
to breathe the air from inside the breathing tank for 10 minutes in 
each session.
There were three treatment sessions per week for 6 months 
(26 weeks). In clinical practice, Epinephrine HFA should ideally be 
used no more than two times per week for patients with mild symp‐
toms of intermittent asthma. At the end of the study, there were 
a total of 78, 10‐minute treatment sessions performed for each 
treatment group of mice. After each session, the breathing tank was 
washed and dried.
2.4 | Determination of the amount of thymol in the 
breathing tank
After spraying the study article into the tank, the actual concen‐
tration of thymol in the air of the breathing tank was determined 
by a validated LC‐MS method. First, the air sampling pump (PCXR8 
Universal	 Sample	 Pump,	 Catalog	 No.	 224‐PCXR8,	 SKC	 Inc)	 was	
connected to the Sorbent Sample Tube (Anasorb CSC, Catalog No. 
226‐01,	SKC	Inc)	using	Tygon	tubing.	The	pump	was	preadjusted	
to	100	mL/min.	The	stirring	fan	was	set	at	400	RPM	and	started	
before the first spray of the test articles. The air sampling unit was 
then inserted into the tank. Thirty seconds after the last spray, 
TA B L E  1   Animal information and treatments in the studies
Study sets Study 1 Study 2
Group No. 1 2 3 4 1 2 3 4
Article and treatments         
Article name Air Vehicle 0.1% Thymol 0.5% Thymol Air Vehicle 0.1% Thymol 0.5% Thymol
Article lot No. — PL000114 PL000314 PL00414 — PL000114 PL000314 PL00414
# of weeks for 
treatment
26 26 26 26 26 26 26 26
# of treatments per 
week
3 3 3 3 3 3 3 3
Total # of treatments 78 78 78 78 78 78 78 78
Mice information         
# of Male Mice 8 8 8 8 8 8 8 8
# of Female Mice 8 8 8 8 8 8 8 8
Subtotal # of Mice 16 16 16 16 16 16 16 16
F I G U R E  1   Eight mice are mounted to 
the tank during treatment
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the air sampling pump was turned on for 10 minutes. This drew 
1000 mL of air through the sampling tube and thymol was cap‐
tured on a coconut charcoal sorbent. Both the front and back ends 
of charcoal were desorbed into 1 mL ethyl acetate. Then, 0.1 mL 
of the ethyl acetate was transferred to 0.9 mL of the HPLC mobile 
phase (50/50 v/v Methanol/H2O with 0.1% formic acid) to analyze 
thymol concentration by LC‐MS.
For each of the two test articles (Article‐1 0.1% thymol, and 
Article‐2 0.5% thymol), three replicates of determinations were 
performed. Between any two tests of these three replicates, a 
method blank was run to assure the data quality. Tank air was also 
sampled and tested before the sprays of thymol, after the sprays 
of thymol, as well as after washing/cleaning of the tank between 
any two treatment sessions in order to ensure removal of residual 
thymol.
2.5 | Determination of the thymol doses for tested 
Article‐1 and Article‐2
The amount of thymol inhaled by the mice was calculated based 
on: (a) the actual concentration of thymol in the air of the tank; 
(b) the mouse breathing time (10 minutes treatment session); and 
(c) the mouse breathing volume per minute, 22.5 mL/min, where 
the breath rates and tidal volume*  in mice are cited from previous 
literature.9
The mouse weekly thymol dose for each of the four treatment 
groups was calculated based on Equation S1 and information from 
Table S2. The relative weekly thymol dose used in a mouse versus 
that of a human was also determined per Equation S2.
2.6 | General health examination of the mice
General health evaluation, including body weight, food intake, sur‐
vival, general appearance, functional behaviors, etc was performed 
on the mice weekly. The mouse body weight data points were meas‐
ured for: (a) four treatment groups; (b) 32 mice per group; and (c) 27 
(0‐26 weeks) times. The general health conditions of the four test 
groups were evaluated and compared.
2.7 | Histopathologic evaluation of the chronic 
toxicity study
After the last treatment, each mouse was sacrificed and four organs: 
(a) lungs, (b) bronchial lymph nodes, (c) nasal passages/nasopharynx, 
and (d) trachea were taken out and preserved in a labeled histology 
container prefilled with 10% Neutral Buffered Formalin. The organs 
were sent to Experimental Pathology Laboratories, Inc (EPL) for his‐
topathologic evaluation. Forty‐five pathologic assessment param‐
eters (PAP) were assessed by EPL.
Hematoxylin and eosin stained (H&E) slides of lung lobes, tra‐
chea, four levels of the nasal turbinates, and bronchial lymph nodes 
were prepared by EPL for microscopic evaluation by a board‐certified 
veterinary pathologist. The EPL rated the pathologic assessment pa‐
rameters (PAPs) as Grade‐0 to 5, where
• GRADE‐0 = “Nothing Abnormal Discovered” (NAD);
• GRADE‐1 = minimal/very few/very small;
• GRADE‐2 = slight/mild/few/small;
• GRADE‐3 = moderate/moderate number/moderate size;
•	 GRADE‐4	=	marked/many/large/moderately	severe;	and
• GRADE‐5 = massive/extensive number/extensive size/severe
To provide an overall picture or profile for pathologic result assess‐
ments, the total abnormal occurrences for a given “Grade‐j” (j = 0–5) 
for a specific PAP, denoted as NAll
j
 , is defined as follows:
where nX
j
 is the number of abnormal occurrences of “Grade‐j” for a 
specific PAP in the entire treatment Group‐X.
Based on the number of abnormal histopathologic occurrences, 
each	of	the	45	PAPs	was	classified	into	two	categories:	If	a	PAP	for	
all combined four test groups had more than three Grade‐1 occur‐
rences, or more than one Grade‐2 occurrence, or any occurrences 
for Grades‐3 to 5, it was classified as a Category‐1 PAP. Otherwise, 
it was classified as a Category‐2 PAP.
In other words, Category‐1 PAPs have more frequent and/or 
more severe pathologic abnormalities than Category‐2 PAPs.
2.8 | Statistical analysis for PAPs with more and/or 
severe pathologic abnormal occurrences
For each Category‐1 PAP, the chronic toxicity of inhaled thymol for 
a given Treatment Group‐X is described as the average chronic tox‐
icity index (“CTI”) of Treatment Group‐X based on a given PAP, de‐
noted as ĀX, which is defined as follows:
where AX
j
 is the CTI of the Treatment Group‐X for the PAP with obser‐
vation Grade‐j; j runs over all possible grades used by EPL report, from 
“nothing abnormal discovered” (NAD), that is, Grade‐0, to Grade‐5 as 
specified by EPL report; nX
j
 is the number of observations with Gradej 
of the PAP in the Treatment Group‐X; NX is the total number of mouse 
organs that were assessed for the PAP for the Treatment Group‐X.
The CTI for a given PAP can be statistically analyzed among dif‐
ferent treatment groups. A one‐sided t test was conducted for the 
following hypothesis:
(1)NAllj =
4∑
X=1
nX
j
Category−1:NAll
1
>3, orNAll
2
>1, orNAll
j
>0,where j=3, 4, or5
Category−2:NAll
1
≤3, orNAll
2
≤1, orNAll
j
=0,where j=3, 4, or5
(2)ĀX=
1
NX
5∑
j=0
AX
j
nX
j
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where 휇X is the CTI for any Category‐1 PAPs for Treatment X, X is 
Treatment Group‐3 (Article‐1, 0.1% thymol),	 or	 Group‐4	 (Article‐2, 
0.5% thymol); 휇Y is the CTI for any one of Category‐1 PAPs for 
Treatment Y, and Y is Treatment Group‐1 (Air), or Group‐2 (Vehicle);
Namely, per Hypothesis given in Equation (3), four types of t test 
were conducted for each CTI of Category‐1 PAP:
(i)  Group‐3 (Article‐1) vs Group‐1 (Air);
(ii)  Group‐3 (Article‐1) vs Group‐2 (Vehicle);
(iii)	 Group‐4	(Article‐2) vs Group‐1 (Air);
(iv)	 Group‐4	(Article‐2) vs Group‐2 (Vehicle);
The study would demonstrate significant difference for chronic toxic‐
ity between the treatment groups if the P‐value of the t test was less 
than .05.
2.9 | Statistical analysis for PAPs with minor and 
mild pathologic abnormal occurrences
To assess Category‐2 PAPs, the number of occurrences for a PAP 
group of a given Treatment X, denoted by gX, was defined as follows:
where k runs over all PAPs included in the PAP group; and nX
k
 is the 
number of occurrence of PAP‐k for the Treatment X.
To conclude that inhalation of thymol results in detectable 
chronic toxicity for a Category‐2 PAP‐group, the following condi‐
tions must be simultaneously satisfied:
• the gX for Treatment Group‐3 (Article‐1, 0.1% thymol)	and	Group‐4	
(Article‐2, 0.5% thymol) must be greater than the gX for Treatment 
Group‐1 (Air) and Group‐2 (Vehicle);
• the gX	for	Treatment	Group‐4	(Article‐2, 0.5% thymol) must be not 
less than the gX for Treatment Group‐3 (Article‐1, 0.1% thymol).
Fisher’s Exact Test (FET) was performed to test the following 
hypotheses:
(3)
H0:𝜇X≤𝜇Y
Ha:𝜇X>𝜇Y
(4)gX=
∑
k
nX
k
(5a,5b)g3>g1; g3>g2,
(5c,5d)g4>g1; g4>g2,
(5e)g4≥g3
(6a)H01:g3≤g1 vs Ha1:g3>g1
(6b)H02:g3≤g2 vs Ha2:g3>g2
(6c)H03:g4≤g1 vs Ha5:g4>g1T
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In order to confirm that inhaled thymol is chronically toxic for a 
Category‐2 PAP‐group, all five P‐values of the hypotheses (6a) to (6e) 
must all be less than .05.
3  | RESULTS
3.1 | The actual thymol concentration in the 
breathing tank
The sprayed amounts of thymol delivered in 15 sprays were 687 and 
3,434	mcg,	respectively,	for	Article‐1	and	Article‐2	(summarized	in	
Table S3). The actual concentration of thymol in the tank sampled 
during 0‐10 minutes after 15 sprays of test articles is the average 
thymol concentration in the breathing tank during the 10 minutes 
of study period for each treatment (Table S3). It was found that: (a) 
after 15 sprays of Article‐1, 71% of thymol was absorbed on the wall 
and inner surface of the tank, while 29% remained at a free gaseous 
state in the air; (b) after 15 sprays of Article‐2, 57% of thymol was 
adsorbed	on	 the	wall	and	 inner	surface	of	 the	 tank,	whereas	43%	
remained in its free gaseous state in the air (Table S3).
3.2 | The amount of thymol inhaled by the mice
The calculated results for the actual thymol doses for Article‐1 and 
Article‐2	 inhaled	 by	 the	mice	were	 57.2	 and	 420	mcg/kg	 for	 each	
treatment, or weekly accumulated inhaled thymol exposure of 171 
and 1261 mcg kg−1 wk−1, respectively, as summarized in Table 2. 
Therefore, the weekly dose of thymol inhaled by mice was 117 to 858 
times of that of the calculated maximum weekly thymol exposed in 
humans based on the Epinephrine HFA labeling, per Equation S2.
3.3 | General health examination of the mice
No abnormal findings in mouse body weight change were observed. In 
total,	3456	mouse	body	weight	data	points	were	measured.	There	was	
no correlation between the mean body weight curves and thymol dose 
inhaled by mice (Figure S1). The mean mouse body weight change pro‐
file (as a function of time) for the treatment groups Group‐2, Group‐3, 
and	Group‐4	has	the	same	trend.	This	indicates	that	even	at	very	high	
doses of thymol (117‐858 times of the human thymol dose due to use 
of Epinephrine HFA), there was no impact on the mouse body weight 
growth over the time period of 6 months.
No abnormal findings in food consumption were observed. The 
mice in all treatment groups appeared to be healthy and no mice died 
during the studies. In fact, there were no abnormalities in appear‐
ance or functional behavior observed in mice throughout the study 
period. Some male mice had the appearance of minor scratches on 
their skin, which were likely the result of fighting within the same 
cage.
3.4 | Histopathologic evaluation
EPL assessed 119, 121, 126, and 121 mouse organs from Groups‐1 
to	4,	 respectively.	 In	 total,	487	mouse	organs	from	128	mice	were	
sent	to	EPL	for	assessment.	The	organs	were	assessed	for	45	PAPs	
as follows: eight PAPs were assessed for lungs; seven for bronchial 
lymph	nodes;	one	PAP	for	trachea;	and	4,	12,	8,	and	5	PAPs	for	four	
different sections of mouse nasal turbinates, Level I, II, III and IV, 
respectively.
EPL	reported	1377,	1391,	1426,	and	1397	PAP	data	points	 for	
Groups‐1	to	4,	respectively.	For	the	entire	study,	there	was	a	total	
of	5,591	pathologic	data	of	45	PAPs.	These	were	assessed	by	EPL	as	
summarized	in	Table	S4.
Based	on	the	pathologic	data,	the	45	PAPs	were	initially	classi‐
fied	 as	 14	Category‐1	 parameters	 and	 31	Category‐2	 parameters.	
(6d)H04:g4≤g2 vs Ha5:g4>g2
(6e)H05:g4<g3vsHa5:g4≥g3
TA B L E  3  Classification	of	45	pathologic	assessment	parameters	(PAPs)
Mouse organs All
Direct classification After combination
Category‐1 Category‐2 Category‐1 Category‐2
Reduced # due to 
the combination
A. Lung 8 3 5 3 5 —
B. Lymph node, bronchi 7 3 4 3 4 —
C1. Nasal turbinate level I 4 1 3 1 3 —
C2. Nasal turbinate level II 12 3 9 4* 6** 2
C3. Nasal turbinate level III 8 1 7 2* 4** 2
C4.	Nasal	turbinate	level	IV 5 2 3 2 3 —
D. Trachea 1 1 0 1 0  
All organs 45 14 31 16 25 4
45 45
*Combined into Category‐1 pathologic parameters. 
**Three very similar Category‐2 PAPs: (a) Dilatation; Bowman's Gland; Duct, (b) Dilatation; Bowman's Gland; Lateral Wall/Turbinate, and (c) 
Dilatation; Bowman's Gland; Septum; are combined as one Category‐1 PAP. 
     |  7 of 10XIE Et al.
However, for pathologic assessments of Nasal turbinate Level II and 
III, there were three very similar Category‐2 PAPs:
(i)  Dilation; Bowman's Gland;
(ii)  Dilation; Bowman's Gland; Lateral Wall/Turbinate, and
(iii) Dilation; Bowman's Gland; Septum.
Since these were all parameters for dilation of Bowman's 
Gland, a combined assessment may provide more meaningful in‐
formation. Therefore, these three PAPs were recategorized into 
one Category‐1 PAP. After the combination/reassignment, there 
were 16 Category‐1 and 25 Category‐2 PAPs as summarized in 
Table 3.
3.5 | Statistical analysis for results of PAPs with 
more and/or severe pathologic abnormal occurrences
Using	 the	 above	 discussed	 statistical	 analysis	 method,	 64	 t tests 
were conducted for the 16 Category‐1 pathologic parameters in 
this study, and all P‐values were greater than .05 as summarized 
in	 Table	 4.	 These	 analyses	 suggest	 that	 there	 are	 no	 statistically	
significant differences in the CTIs for the 16 Category‐1 PAPs be‐
tween	the	mice	that	 inhaled	high	dose	of	thymol	 (Groups‐3	and	4,	
d = 117 and 858, respectively), and those with no thymol inhaled 
(Groups‐1 and 2, d = 0).
3.6 | Statistical analysis for results of PAPs with 
minor and mild pathologic abnormal occurrences
There were a very small number of occurrences of pathologic ab‐
normalities observed for the 25 Category‐2 PAPs, as summarized 
in Table 5. These 25 PAPs are grouped into six mouse organ PAP 
groups (ie, lung, bronchial lymph nodes, and nasal turbinate levels 
I, II, III, and IV). There was no Category‐2 PAP for Trachea. In total, 
24	 Fisher	 Exact	 Tests	 (FET)	 were	 conducted	 for	 the	 four	 treat‐
ments of the six Category‐2 PAP groups. The FET results demon‐
strate no significant difference in chronic toxicity when comparing 
mice under long‐term, repeated exposure of high doses of inhaled 
thymol	 (Groups‐3	 and	 4)	 versus	 those	 with	 no	 thymol	 inhaled	
(Groups‐1 and 2).
TA B L E  4   P‐Values of chronic toxicity evaluation for inhaled thymol based on the 16 Category‐1 PAPs with t test
#
Treatment group pairs
Group‐3 vs 
Group‐1
Group‐3 vs 
Group‐2
Group‐4 vs 
Group‐1
Group‐4 vs 
Group‐2
Treatment dose pairs (weekly mouse thymol dose relative to human 
dose due to use of epinephrine HFA) 117 vs 0 117 vs 0 858 vs 0 858 vs 0
 A. Lung # Examined 32 32 32 32
1 • Congestion P‐value .91 .93 .50 .62
2 • Hemorrhage; acute P‐value .89 .72 .79 .57
3 • Hyperplasia; bronchioloalveolar; focal P‐value .21 .14 .84 .84
 B. Lymph node, bronchi # Examined 23 25 30 26
4 • Focus; mast cells; sinus P‐value .64 .45 .87 .69
5 • Hemorrhage; acute P‐value .97 .95 .76 .63
6 • Pigment; brown macrophages P‐value .21 .59 .28 .70
 C1. Nasal turbinate level I # Examined 32 32 32 32
7 • Eosinophilic substance; Septum P‐value .58 .79 .58 .77
 C2. Nasal turbinate level II # Examined 32 32 32 32
8 • Dilatation; Bowman's Gland; Duct, or Lateral 
Wall/Turbinate, or Septum
P‐value .16 .29 .25 .39
9 • Eosinophilic Substance; Septum P‐value .64 .65 .64 .64
10 • Hemorrhage; Acute; Nasolacrimal Duct P‐value .37 .50 .50 .66
11 • Hyperplasia; Bowman's Gland; Septum P‐value .50 .65 .35 .50
 C3. Nasal turbinate leveL III # Examined 32 32 32 32
12 • Dilatation; Bowman's Gland; Duct, or Lateral 
Wall/Turbinate, or Septum
P‐value .50 .50 .63 .63
13 • Eosinophilic Substance; Septum P‐value .37 .56 .31 .50
 C4.	Nasal	turbinate	level	IV # Examined 32 32 32 32
14 • Dilatation; Bowman's Gland; Septum P‐value .98 .84 .92 .50
15 • Hyperplasia; Bowman's Gland; Septum P‐value .98 .84 .79 .27
 D. Trachea # Examined 32 32 32 31
16 • Dilation; Gland with Cell Debris P‐value .95 .80 .83 .48
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4  | DISCUSSION
In the 6‐month chronic toxicity studies in mice, there were no test 
article‐related findings observed. According to the EPL evaluation, 
the findings in the lung were all considered incidental background 
findings common to this species and age or a consequence of eu‐
thanasia procedures. A benign bronchiole‐alveolar adenoma was 
found in the lung from a Group‐1 air control female mouse. Minimal 
to mild bronchiole‐alveolar hyperplasia was seen in two males, one 
from the vehicle group and one from the low‐dose 0.1% thymol HFA 
group. In the lung of one high‐dose female, the white raised area 
was correlated microscopically with minimal alveolar macrophage 
accumulation, another background finding common to this species.
For the bronchial lymph node, the findings were generally min‐
imal and considered not to reflect toxicity of the administered test 
article. In one high‐dose male, minimal numbers of neutrophils were 
observed in the medullary cords, with no evidence of concurrent 
infection. In two of the high‐dose females, the high endothelial ve‐
nules in the cortex of the bronchial lymph node were more promi‐
nent than observed in other lymph nodes. High endothelial venules 
are specialized postcapillary venous swellings that enable lympho‐
cytes circulating in the blood to directly enter in the lymph node. 
High endothelial venules are a normal feature of the lymph node.
For the nasal turbinates, presence of minimal to mild eosino‐
philic globules (droplets) in the epithelium of the nasal cavity was 
observed. However, this finding occurred in only two of a total of 
32 animals from the high‐dose (0.5% thymol HFA) and in one of 32 
animals at the low‐dose (0.1% thymol HFA). With so few animals af‐
fected, this finding is likely related to the aging of the animal than to 
treatment with inhaled thymol HFA.
There were no test article‐related findings seen in the trachea in 
this study. Overall, it is evident that thymol inhaled by the mice during 
the 6‐month treatment, even in the highest study dose group (858 
times of the maximum human dose from use of Epinephrine HFA) did 
not produce any chronic toxic effects on the lung or respiratory tracts.
The absence of histopathological evidence of any chronic toxic 
effects in the lung or respiratory tract from the doses of inhaled thy‐
mol administered in the 6‐month studies is likely due to the fact that 
the bioavailability was far below the toxic levels.
It is also worth noting that the very rapid breathing rate of the 
mouse 9 suggests that most of the thymol inhaled probably depos‐
ited in the nose and upper airway with relatively little actually reach‐
ing the lung. Lung scintigraphy studies in humans have shown that 
the faster the inspiratory flow, the less deposition of the respira‐
ble fraction of an orally administered therapeutic aerosol (MMAD 
3‐5 µm) in the lower respiratory tract.10‐12 Therefore, most of the 
dose delivered to the mice was probably deposited in the nose (with 
nasal breathing) and, to a lesser extent, in the oral cavity and naso‐
pharynx and then swallowed.
The results of this chronic toxicity study are consistent with the 
fact that thymol is classified as Generally Recognized as Safe (GRAS) 
by the FDA.4
5  | CONCLUSION
Overall, neither data from literature nor results from chronic tox‐
icity studies presented herein provide any evidence for chronic 
toxicity of inhaled thymol. There were no nonclinical findings that 
would preclude the safe administration of thymol via inhalation to 
humans.
Based on this chronic toxicity study of mouse model, the no‐
observed‐adverse‐effect level (NOAEL) of thymol by inhalation is 
0.42	mg/kg	for	a	single	treatment	and	1.26	mg	kg−1 wk−1 for a long‐
term treatment.
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